CN102399806A - Porcine epidemic diarrhea S1 protein fusion gene, recombinant bacillus megaterium strain and application - Google Patents

Porcine epidemic diarrhea S1 protein fusion gene, recombinant bacillus megaterium strain and application Download PDF

Info

Publication number
CN102399806A
CN102399806A CN2011104247048A CN201110424704A CN102399806A CN 102399806 A CN102399806 A CN 102399806A CN 2011104247048 A CN2011104247048 A CN 2011104247048A CN 201110424704 A CN201110424704 A CN 201110424704A CN 102399806 A CN102399806 A CN 102399806A
Authority
CN
China
Prior art keywords
ala
leu
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011104247048A
Other languages
Chinese (zh)
Inventor
张金林
马立保
胡晓芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WUHAN HUAYANG ANIMAL PHARMACEUTICAL CO Ltd
Original Assignee
WUHAN HUAYANG ANIMAL PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WUHAN HUAYANG ANIMAL PHARMACEUTICAL CO Ltd filed Critical WUHAN HUAYANG ANIMAL PHARMACEUTICAL CO Ltd
Priority to CN2011104247048A priority Critical patent/CN102399806A/en
Publication of CN102399806A publication Critical patent/CN102399806A/en
Priority to CN201210523652.4A priority patent/CN103194472B/en
Pending legal-status Critical Current

Links

Images

Abstract

The invention discloses a porcine epidemic diarrhea S1 protein fusion gene, recombinant bacillus megaterium strain and application. An antigen fusion gene shown as SEQ ID No. 1. is obtained by connecting an antigen locus of porcine epidemic diarrhea virus (PEDV) S glycoprotein and a cell wall anchoring sequence. The invention further constructs a secretion expression vector containing the antigen fusion gene, and secretion expression vector is converted into the bacillus megaterium to express recombinant protein on the cell wall or surface of the bacillus megaterium. Immunoblotting experiments indicate that the expressed recombinant protein can react with PEDV immune serum and has the same antigenicity as PEDV natural antigens. Immunofluorescent tests of live bacteria which are subjected to induced expression indicate that the expressed recombinant protein is positioned to the surfaces of the bacteria. Experiment results indicate that the recombinant protein can be prepared into safe and effective mucous immune live vaccines for preventing and treating porcine epidemic diarrhea.

Description

Porcine epizootic diarrhea S 1Protein fusion gene and reorganization bacillus megaterium and application
Technical field
The recombinant bacterial strain that the present invention relates to antigen fusion gene and contain this antigen fusion gene relates in particular to porcine epizootic diarrhea S 1Protein fusion gene and the expression vector that contains this fusion gene; The invention further relates to the reorganization bacillus megaterium bacterial strain and their application in preparation control porcine epizootic diarrhea vaccine that contain this expression vector, belong to the prevention and control field of porcine epizootic diarrhea.
Background technology
Porcine epizootic diarrhea (PEDV) is a kind of acute height contagious disease that is caused pig by coronavirus, is characteristic with watery diarrhea, vomiting and dehydration, and this disease worldwide extensively distributes, and harm is serious, brings heavy economic losses to pig industry.Virus is main to have the characteristics of tangible intestinal tissue preferendum through the intestinal tract infections pig, and except that humoral immunization and cellular immunization, local intestines mucosa immunity system is being brought into play irreplaceable effect in anti-PEDV infection immunity process.
PEDV has typical coronavirus structure; Form by 4 kinds of primary structure albumen; Nucleocapsid protein (N), membranin (M), glycosylated spike protein (S) and the little envelope protein (E) that is respectively phosphorylation wherein S gp carries main bone-marrow-derived lymphocyte antigenic determinant and can induce and produce neutralizing antibody and the important structure albumen that immanoprotection action is provided; Therefore, S albumen to virus infection, bring into play its pathogenic and decision host cell parent preferendum aspect and play a crucial role.PEDV infects to have and significantly has a liking for intestines property, and secretory IgA antibody is the key factor that protection pig body does not receive PEDV to infect and avoid falling ill, and behind the oral immunity, in intestinal juice and serum, all can detect sIgA antibody, but not the oral route inoculation then detects less than sIgA.Piglet can obtain source of parents sIgA through colostrum, produces the passive immunization protection of popularity diarrhoea.
Conventional inactivated vaccine and less toxic vaccine have played active effect in these two kinds of diseases of control, obtain good effect, but still have some problems, and be poor like the inactivated vaccine immunogenicity, can not effectively induce slgA, and opposing is infected; The postvaccinal animal body of less toxic vaccine row loose virus, virus virulence possibly return strong etc., in addition must be through the injecting pathway immunity.To the characteristics of porcine epizootic diarrhea, adopting oral immunity is ideal prevention approach comparatively, but how to avoid gi tract to antigenic destruction and effectively induce immune response become key.
Summary of the invention
One of the object of the invention provides a kind of porcine epizootic diarrhea S 1Proteantigen fusion gene and encoded protein thereof;
Two of the object of the invention provides and contains above-mentioned porcine epizootic diarrhea S 1The expression vector of proteantigen fusion gene;
Three of the object of the invention provides the recombinant host that contains above-mentioned expression vector bacterial strain.
To achieve these goals, one aspect of the present invention provides a kind of S by PEDV gp S 1Antigen site and streptococcus pyogenes cell walls anchor series (CWA M6) connecting the fusion gene that obtains, its polynucleotide sequence is shown in the SEQ ID No.1.
The present invention finds out the 22-505aa section sequence of coding S gp, through the Linker ((GGGGS) of flexibility according to the PEDV complete genome sequence AF353511 of Genbank login 3) with the S of PEDV 1Antigen site gene and cell walls anchor series (CWA M6) couple together, with this sequence called after MLS 1(SEQ ID No.1).That considers the bacillus megaterium codon has a liking for situation partially; The present invention is in order to improve the expression of heterologous gene in the host bacterium; And guarantee under the constant situation of amino acid after the translation rare codon Threonine (ACG), Histidine (CAC), l-arginine (CGG, CGA), L-Ala (GCG) and leucine (CTC, CTG) etc. to be changed.In addition, at MLS 1Upstream and downstream introduce Bgl II restriction enzyme site and SphI restriction enzyme site respectively.
Another aspect of the present invention provides by fusion gene encoded protein shown in the SEQ ID No.1, and its aminoacid sequence is shown in the SEQ ID No.2.。
Another aspect of the present invention provides and contains said porcine epizootic diarrhea S 1The expression vector of protein fusion gene; For example, the antigen fusion gene shown in the SEQ ID No.1 of the present invention is carried out being connected of operability with expression vector pHIS1525, obtaining can be at the outside surface of bacillus megaterium or the secretion expression carrier of its cell walls expression fusion gene.
Infect and sIgA has the characteristics of vital role in resist the disease to the PEDV per mucous membrane, the present invention has made up expression PEDV S 1Proteic reorganization bacillus megaterium expression system as a kind of oral vaccine, through the specificity sIgA that stimulates the Intestinal Mucosal Immunity system to produce, reaches the purpose that stops pathogen infection.
Thus, the reorganization bacillus megaterium bacterial strain that provides strain expression porcine epizootic diarrhea S1 protein fusion gene more on the one hand of the present invention can be prepared into the safe and effective mucosal immunity live bacterial vaccines of control porcine epizootic diarrhea by enough its.
The present invention carries out the fusion gene shown in the SEQ ID No.1 double digestion with secretion expression carrier pHIS1525, is connected and changes host bacterium bacillus megaterium WH320 cell over to through protoplast transformation, obtains to contain reorganization bacillus megaterium (Bacillus megaterium) bacterial strain (WH320-pHIS1525-MLS of recombinant plasmid 1); Its microbial preservation number is: CCTCC No:M2011445; The classification name is: Bacillus megaterium WH320-pHIS1525-MLS 1The preservation time is on December 5th, 2011; Depositary institution is: Chinese typical culture collection center; The preservation address is: Chinese Wuhan Wuhan University.
Further, the present invention bacillus megaterium bacterial strain (WH320-pHIS1525-MLS that will recombinate 1) use to add final concentration be that 0.2% wood sugar is induced, and fusion gene is expressed on the thalline surface; Immunoblot experiment shows; Expressed recombinant protein can react with the TGEV immune serum; Showing that recombinant protein is the same with the TGEV natural antigen has an identical antigenicity, can be used in the safe and effective mucosal immunity live bacterial vaccines that is prepared into the control porcine epizootic diarrhea.Indirect immunofluorescence detects and confirms that also expressing protein is present on the thalline; Viable bacteria body immunofluorescent test behind the abduction delivering shows; Expressed albumen Primary Location is in the surface of thalline; There is the target protein on thalline surface, is antigenic substance effective stimulus immunity system, improve antibody horizontal and established important basic substance.
The present invention is a purpose with the first line of defence that blocking-up infectious intestinal disease disease pathogen infects in experimental design; Nontoxic bacillus megaterium expression system safe in utilization, bacillus megaterium does not produce intracellular toxin, does not produce the outer Sumizyme MP of born of the same parents; Help expressed proteic stable accumulation; Plasmid is stable, can stability and high efficiency ground expressing protein, and relatively more suitable industrial fermentation production.Genus bacillus can consume a large amount of free oxygens after the enteron aisle field planting simultaneously, causes anaerobic environment, can reduce the field planting of aerophil to enteron aisle.Also help the growth of anerobess such as lactobacillus spp and bifidus bacillus, cause intravital probiotics to increase and the pathogenic bacterium minimizing, keep the intestinal microecology system balancing.
The term definition that arrives involved in the present invention
Only if in addition definition, otherwise all technology used herein and scientific terminology all have with those skilled in the art and understand identical implication usually.Though in practice of the present invention or test, can use any method, device and the material similar or equivalent, describe preferred method, device and material now with person described herein.
Term " recombinant host bacterial strain " or " host cell " mean the cell that comprises polynucleotide of the present invention; And no matter use which kind of method to insert, for example directly absorb to produce recombinant host cell, known other method in transduction, f pairing or the affiliated field.Exogenous polynucleotide for example can remain, and the nonconformity carrier of plasmid perhaps can be integrated in the host genome.
Term " polynucleotide " means deoxyribonucleotide, dezyribonucleoside, ribonucleoside or ribonucleotide and the polymkeric substance thereof of sub-thread or bifilar form.Only if specific limited, otherwise the nucleic acid of the known analogue that contains natural nucleotide contained in said term, said analogue have the binding characteristic that is similar to reference nucleic acid and carry out metabolism with the mode of the Nucleotide that is similar to natural generation.Only if other specific limited, otherwise said term also means oligonucleotide analogs, it comprises PNA (PNAG3), used DNA analogue (thiophosphatephosphorothioate, phosphoramide acid esters or the like) in antisense technology.Unless otherwise, otherwise specific nucleic acid sequence is also impliedly contained its conservative varient of modifying (including, but is not limited to degenerate codon replaces) and complementary sequence and clear and definite specified sequence.Specific; Can realize that through mixing base and/or the substituted sequence of Hypoxanthine deoxyriboside residue degenerate codon replaces (Batzer et al., Nucleic Acid Res.19:5081 (1991) through producing one of them or selected more than one (or all) codon the 3rd; Ohtsuka et al., J.Biol.Chem.260:2605-2608 (1985); Rossolini et al., Mol Cell.Probes8:91-98 (1994)).
Term " expression " is foreign gene transcribing or/and translate in the host.
Term " polypeptide ", " peptide " and " albumen " exchange in this article and use to mean the polymkeric substance of amino-acid residue.That is, be equally applicable to describe peptide and describe albumen and vice versa to the description of polypeptide.Said term is applicable to natural generation aminoacid polymers and one of them or the aminoacid polymers that above amino-acid residue is a non-naturally encoded amino acids.As used herein, the amino acid chain of any length contained in said term, and it comprises full-length proteins (being antigen), and wherein amino-acid residue connects via the covalency peptide bond.
Description of drawings
Fig. 1 PCR product electrophoresis result; 1-3, MLS 1The PCR product; M, DL2000.
The enzyme of Fig. 2 expression plasmid pHIS1525 is cut detection; 1-2, plasmid pHIS1525 enzyme are cut product; M, DL2000.
Fig. 3 PCR product electrophoresis result; 1-3:Bgl II and SphI double digestion, the fragment that obtains is about 7500bp, 1920bp respectively; M1:DL2000; M2:DL15000.
The SDS-PAGE of Fig. 4 expression product and Western-blot analyze; M: protein molecular weight standard; 1: the protein after reorganization bacillus megaterium WH320-pHIS1525 induces; 2-4, reorganization bacillus megaterium WH320-pHIS1525-MLS 1Protein after inducing; 5: the proteinic immunoblotting after reorganization bacillus megaterium WH320-pHIS1525-MLS induces.
The indirect immunofluorescence of Fig. 5 expression product detects (* 40); The IFA test-results of A:WH320-pHIS1525-MLS reorganization bacterium, somatic cells has distributed the intensive yellow-green fluorescence; The IFA test-results of B:WH320-pHIS1525 reorganization bacterium does not have fluorescence, and thalline takes on a red color.
Embodiment
Further describe the present invention below in conjunction with specific embodiment, advantage of the present invention and characteristics will be more clear along with description.But these embodiment only are exemplary, scope of the present invention are not constituted any restriction.It will be understood by those skilled in the art that and down can make amendment with form or replace without departing from the spirit and scope of the present invention, but these modifications and replacing all fall in protection scope of the present invention the details of technical scheme of the present invention.
Embodiment 1MLS 1The structure and the evaluation of gene bacillus megaterium secretion expression carrier
1 epitope sequence MLS 1Design with synthetic
According to the PEDV complete genome sequence AF353511 of Genbank login, find out the 22-505aa section sequence of coding S gp, through the Linker ((GGGGS) of flexibility 3) with the S of PEDV 1Antigen site gene and cell walls anchor series (CWA M6) couple together this sequence called after MLS 1(SEQ ID No.1).Rare codon Threonine (ACG), Histidine (CAC), l-arginine (CGG, CGA), L-Ala (GCG) and leucine (CTC, CTG) etc. are changed, but do not change its coded amino acid.At MLS 1Upstream and downstream introduce BglII restriction enzyme site and SphI restriction enzyme site respectively.With the MLS that designs 1Sequence is carried out synthetic, has made up recombinant plasmid pMD18-MLS 1
PMD18-T Simple Vector is available from TaKaRa (Dalian) company, pMD18-MLS 1Concrete building process following:
The pcr amplification goal gene, in the PCR reaction tubes according to adding reagent and solution shown in the table 1.
Table 1MLS 1The PCR reaction system
Figure BDA0000121376800000051
P1:5’-GA AGA TCT ATGGATGTCACTAGGTGCCAGT 3’
P2:5’-ACAT GCA TGC GTTTTCTTCTTTGCGTTTTACA 3’
Be positioned in the PCR appearance after mixing is also centrifugal, behind 94 ℃ of preparatory sex change 5min, circulate as follows: 94 ℃, 30s; 54 ℃, 30s; 72 ℃, 30s.30 circulations are extended 10min for back 72 ℃.Pcr amplification is got 5 μ L products and is observed with 1% agarose gel electrophoresis after accomplishing.And reclaim test kit specification sheets recovery enzyme with reference to dna gel and cut product, reclaiming the test kit specification sheets with reference to dna gel and reclaim the PCR reaction product, operation steps is following:
With 100 μ L PCR products electrophoresis in 1% sepharose; Under UV-lamp, downcut the sepharose that contains target DNA; Add DE-A (for dna gel reclaims the reagent in the test kit) solution of 3 gel volumes, mix the back in 75 ℃ of heating and melting.Add DE-B (for dna gel reclaims the reagent in the test kit) solution of 0.5 DE-A volume, mix.Get above mixed solution, be transferred to and centrifugally in the DNA preparation pipe abandon filtrating.To prepare pipe and put back centrifuge tube, and add 0.5ml W1 (for dna gel reclaims the reagent in the test kit) solution, the centrifugal 30s of 12000rpm abandons filtrating.To prepare pipe and put back centrifuge tube, and add 0.7ml W2 (for dna gel reclaims the reagent in the test kit) solution, the centrifugal 30s of 12000rpm abandons filtrating, repeats this step once.To prepare pipe and put back in the centrifuge tube the centrifugal 1min of 12000rpm.Preparation pipe is placed clean 1.5ml centrifuge tube, add in right amount (20 μ L) water or the elutriant room temperature leaves standstill 1min, the centrifugal 1min eluted dna of 12000rpm in preparation film centre.Fetch to receive in product 1 μ L 1% sepharose and carry out electrophoresis, detect and reclaim the result.And it is subsequent use in-20 ℃ of preservations.
The PCR product is connected and conversion with cloning vector
Pressing pMD18-T Simple Vector specification sheets is connected the PCR product that reclaims with pMD18-T Simple Vector.Linked system is seen table 2:
Table 2 ligation system
Figure BDA0000121376800000061
Centrifugal behind the mixing, place 16 ℃ of water-baths to connect 4h, 4 ℃ are spent the night.After the connection, contain MLS 1The plasmid called after pMD18-MLS of sequence 1
The structure of 2 recombinant expression vectors
With pMD18-MLS 1The vector plasmid pHIS1525 of plasmid and secreting, expressing (plasmid pHIS1525 purchases the company in MoBiTec) is respectively with reclaiming behind the Bgl II+SphI double digestion, couples together with T4DNA ligase and is built into recombinant plasmid pHIS1525-MLS 1
2.1MLS 1The enzyme of sequence is cut and is reclaimed
The endonuclease reaction system is seen table 3.
Table 3Bgl II, SphI double digestion reaction system
Figure BDA0000121376800000062
Figure BDA0000121376800000071
100 μ L enzymes are cut product electrophoresis in 1% sepharose, and reclaim test kit specification sheets recovery enzyme with reference to dna gel and cut product, reclaim the test kit specification sheets with reference to dna gel and reclaim the PCR reaction product, operation steps is following:
With 100 μ L PCR products electrophoresis in 1% sepharose, under UV-lamp, downcut the sepharose that contains target DNA, add the DE-A solution of 3 gel volumes, mix the back in 75 ℃ of heating and melting.Add the DE-B solution of 0.5 DE-A volume, mix.Get above mixed solution, be transferred to and centrifugally in the DNA preparation pipe abandon filtrating.To prepare pipe and put back centrifuge tube, and add 0.5ml W1 solution, the centrifugal 30s of 12000rpm abandons filtrating.To prepare pipe and put back centrifuge tube, and add 0.7ml W2 solution, the centrifugal 30s of 12000rpm abandons filtrating, repeats this step once.To prepare pipe and put back in the centrifuge tube the centrifugal 1min of 12000rpm.Preparation pipe is placed clean 1.5ml centrifuge tube, add in right amount (20 μ L) water or the elutriant room temperature leaves standstill 1min, the centrifugal 1min eluted dna of 12000rpm in preparation film centre.Fetch to receive in product 1 μ L 1% sepharose and carry out electrophoresis, detect and reclaim the result, the big or small about 1920bp (Fig. 1) that conforms to expected results of nucleotide fragments.
2.2 the enzyme of the carrier pHIS1525 of bacillus megaterium secreting, expressing is cut and is reclaimed
A large amount of enzymes of the carrier pHIS1525 of bacillus megaterium secreting, expressing are cut, and the endonuclease reaction system is seen table 4.
Table 4BglII, SphI double digestion reaction system
Figure BDA0000121376800000072
100 μ L enzymes are cut product electrophoresis in 1% sepharose, and reclaim test kit specification sheets recovery enzyme with reference to dna gel and cut product, more than the concrete steps reference, fetch to receive in product 1 μ L 1% sepharose and carry out electrophoresis (Fig. 2), detect and reclaim the result.And it is subsequent use in-20 ℃ of preservations.
2.3MLS 1The structure of gene bacillus megaterium secretion expression carrier
The enzyme of above step preparation is cut purified product connect, linked system is seen table 5.
Table 5MLS 1The carrier pHIS1525 ligation system of gene secreting, expressing
Figure BDA0000121376800000081
After 16 ℃ of water-baths connected 4h, 4 ℃ were spent the night.
The purifying that connects product: will connect product and be transferred in the 1.5ml centrifuge tube, add the absolute ethyl alcohol mixing gently of 3mol/L sodium-acetate (pH5.2) and the 50 μ L of 2.0 μ L, place-20 ℃, 1h after; 4 ℃, the centrifugal 30min of 12000rpm carefully remove supernatant, add 70% ethanol of 500 μ L; 4 ℃, the centrifugal 5min of 12000rpm carefully remove supernatant, and be air-dry to there not being the ethanol smell; Add 4 μ L sterilization deionized water dissolving deposition ,-20 ℃ of preservations are subsequent use.
2.4pHIS1525-MLS 1The double digestion of plasmid, PCR identify
(1) with the above-mentioned plasmid that reclaims, with Bgl II, SphI double digestion, the endonuclease reaction system is seen table 6.
Table 6pHIS1525-MLS 1The double digestion reaction system of plasmid
Figure BDA0000121376800000082
The above component of mixing gently, 37 ℃ of water-bath 4h get 5 μ L enzymes and cut product and observe with 1% agarose gel electrophoresis.Can cut out the purpose fragment and pHIS1525 carrier plasmid of the same size is accredited as the positive.
(2) the above-mentioned plasmid that extracts is diluted 100 times with sterile purified water, get 2 μ L, carry out PCR and identify as template; Fetch to receive in product 1 μ L 1% sepharose and carry out electrophoresis; Detect and reclaim the result, the big or small about 1920bp (Fig. 3) that conforms to expected results of nucleotide fragments shows MLS 1Gene has been inserted between the restriction enzyme site Bgl II, SphI of expression vector pHIS1525, with the positive recombinant plasmid called after pHIS1525-MLS that obtains 1With the positive recombinant bacterial strain called after WH320-pHIS1525-MLS that obtains 1Bacterial strain.
Embodiment 2MLS 1Conversion of gene bacillus megaterium and expression are identified
The preparation of 1 bacillus megaterium protoplastis
Picking one ring bacillus megaterium (Bacillus megaterium) WH320 (purchasing the company in MoBiTec) rules on the LB flat board; 37 ℃ of incubated overnight; From above-mentioned dull and stereotyped picking one single colony inoculation to 1 * AB3 liquid nutrient medium, 37 ℃ of incubated overnight of 200r/min; Get above-mentioned seed liquor 1ml and change the 250ml triangular flask that 50ml 1 * AB3 substratum is housed over to, 200r/min37 ℃ is cultured to OD600 ≈ 1.0 centrifugal collection thalline, adds 5ml SMMP solution suspension thalline; Bacterium liquid is changed in the 100ml triangular flask, and adding final concentration is the N,O-Diacetylmuramidase of 0.1mg/ml, puts 37 ℃ of water bath heat preservation 30min, uses the formation of microscopic examination protoplastis therebetween, and being formed on about half of protoplastis is advisable; Centrifugal 10min collects protoplastis, with an amount of SMMP buffer solution elution once, uses 5ml SMMP solution suspension thalline at last.
2 huge bud pole bacterium protoplast transformation
Get 100 μ L protoplastiss in 1.5ml EP pipe, add about 1 μ g recombinant expression vector plasmid, 300 μ LpEG-P successively, be incubated 2min under the room temperature; Adding 1ml SMMP solution slowly mixes; The centrifugal 10min of 3000r/min removes supernatant gently under the room temperature, generally can't see any deposition this moment; Add 500 μ L SMMP solution in the EP pipe, it is put 37 ℃ cultivate 90min; 2.5ml CR5-top top-layer agar is placed 60 ℃ of water-baths subsequent use (this agar is with 5ml centrifuge tube dress); Get the CR5-top top-layer agar that 200 μ L bacterium liquid are added to preheating in advance behind the 90min, be poured into after mixing on the LB flat board and (contain 10 μ g/ml tsiklomitsins), with the glass rod coating evenly, 37 ℃ of overnight cultures.Simultaneously, transform as positive control by above step with the empty carrier that does not contain goal gene.
3 reorganization bacillus megaterium MLS 1The abduction delivering of gene and evaluation
WH320-pHIS1525 and WH320-pHIS1525-MLS 1Inoculation 10ml LB liquid nutrient medium, 37 ℃ of thermal agitation overnight cultures are inoculated in the 50ml LB liquid with 5% inoculum size respectively and carry out amplification cultivation, take out one bottle of WH320-pHIS1525-MLS behind the cultivation 4h 1As the sample before inducing, all the other add final concentration is that 0.2% wood sugar is induced 6-9h, gets engineering bacteria WH320-pHIS1525-MLS respectively 1Induce preceding, induce back 6-9h supernatant and positive control bacterial strain (WH320-pHIS1525) supernatant 6ml; Behind the acetone precipitation of 4 times of volumes, obtain supernatant albumen; Add boil 5min behind 40 μ L2 * the go up appearance buffer mixing after, centrifuging and taking 20 μ L supernatants carry out the SDS-PAGE electrophoresis detection.
The immune marking (western-blot) of 4 expression products is analyzed
Gel after the above-mentioned electrophoresis end is transferred to albumen on transfer printing damping fluid equilibrated nitrocellulose filter energized, 0.5-1mA/cm through transfer device 2Transfer printing 1h.After transfer printing finished, the anti-PEDV serum of rabbit was as first antibody, and as SA, the 20min that develops the color in the 4-chloro-1-naphthols substrate chromophoric solution detects the antigenic activity of expression product with the horseradish peroxidase-labeled goat anti-rabbit igg.
The result shows, reorganization bacillus megaterium WH320-pHIS1525-MLS 1The band of expression is arranged at about 64kDa place, and goal gene is having obtained effectively expressing (shown in arrow) in the engineering bacteria (Fig. 4), and along with the increase of induction time, the content of target protein also progressively increases in the supernatant, and does not contain target protein in the positive control bacterium supernatant.Detect through Western-blot and to show that recombinant protein has the ability that the antiserum(antisera) with the preparation of PEDV totivirus reacts, and have good specificity, i.e. reactionogenicity.
5 indirect immunofluorescences
Get positive reorganization bacterium that 12h cultivates with empty carrier contrast bacteria liquid culture 0.5mL is centrifugal remove supernatant after, wash 3 times the anti-TGEV antiserum(antisera) in adding rabbit source respectively with the PBS low-speed centrifugal; Suspend and mix back 37 ℃ of effect 30min, the centrifugal supernatant that goes, PBS is centrifugal to wash thalline 3 times; The anti-rabbit fluorescent mark that contains Evans Blue two that adds dilution is anti-, suspends to mix back 37 ℃ of effect 30min, the centrifugal supernatant that goes; PBS is centrifugal to wash thalline 3 times, and the bacterial sediment thing is suspended in 200 μ L PBS, gets an amount of smear; Seasoning, cold acetone is 30min fixedly, dry back fluorescence microscope.
With WH320-pHIS1525-MLS 1Reorganization bacterium and the WH320-pHIS1525 contrast indirect immunofluorescence experiment result that bacterium carried out show, reorganization bacterium WH320-pHIS1525-MLS 1The visible significantly yellow-green fluorescence of fluorescence microscopy shows also that thus the expressed foreign protein of reorganization bacterium is the surface location that is present in thalline; WH320-pHIS1525 does not find green fluorescence, and thalline is dyed redness (Fig. 5).
< 110>Wuhan Huayang Animal Pharmaceutical Co., Ltd.
<120>Porcine epizootic diarrhea S 1Protein fusion gene and reorganization bacillus megaterium and application
<130> DQXL-0018
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 1920
<212> DNA
<213> Artifical sequence
<220>
<221> CDS
<222> (1)..(1920)
<400> 1
aug gat gtc act agg tgc cag tct act act aac ttt agg cgt ttc ttt 48
Met Asp Val Thr Arg Cys Gln Ser Thr Thr Asn Phe Arg Arg Phe Phe
1 5 10 15
tca aaa ttt aat gtt cag gca cct gcc gtc gtc gtt ttg ggt ggt tac 96
Ser Lys Phe Asn Val Gln Ala Pro Ala Val Val Val Leu Gly Gly Tyr
20 25 30
cta cct agt atg aac tct tct agc tgg tac tgt ggc aca ggc att gaa 144
Leu Pro Ser Met Asn Ser Ser Ser Trp Tyr Cys Gly Thr Gly Ile Glu
35 40 45
act gct agt ggc gtt cat ggt att ttt ctc agc tac atc gat tct ggt 192
Thr Ala Ser Gly Val His Gly Ile Phe Leu Ser Tyr Ile Asp Ser Gly
50 55 60
cag ggc ttt gag att ggc att tct caa gag cct ttt gat cct agt ggt 240
Gln Gly Phe Glu Ile Gly Ile Ser Gln Glu Pro Phe Asp Pro Ser Gly
65 70 75 80
tac cag ctt tat tta cat aag gcc act aat ggt aac act aat gct att 288
Tyr Gln Leu Tyr Leu His Lys Ala Thr Asn Gly Asn Thr Asn Ala Ile
85 90 95
gca cgt ctg cgc att tgc cag ttt ccc gat aat aaa aca ttg ggc cct 336
Ala Arg Leu Arg Ile Cys Gln Phe Pro Asp Asn Lys Thr Leu Gly Pro
100 105 110
act gtt aat gat gtt aca aca ggt cgt aac tgc cta ttc aac aaa gcc 384
Thr Val Asn Asp Val Thr Thr Gly Arg Asn Cys Leu Phe Asn Lys Ala
115 120 125
att cca gct tat atg cgt gat gga aaa gat att gtt gtc ggc ata aca 432
Ile Pro Ala Tyr Met Arg Asp Gly Lys Asp Ile Val Val Gly Ile Thr
130 135 140
tgg gat aat gat cgt gtc act gtt ttt gct gac aag atc tat cat ttt 480
Trp Asp Asn Asp Arg Val Thr Val Phe Ala Asp Lys Ile Tyr His Phe
145 150 155 160
tat ctt aaa aat gat tgg tcc cgc gtt gct aca aga tgt tac aat cgc 528
Tyr Leu Lys Asn Asp Trp Ser Arg Val Ala Thr Arg Cys Tyr Asn Arg
165 170 175
aga agt tgt gct atg caa tat gtt tat aca cct acc tac tac atg ctt 576
Arg Ser Cys Ala Met Gln Tyr Val Tyr Thr Pro Thr Tyr Tyr Met Leu
180 185 190
aat gtt act agt gca ggt gag gat ggc att tat tat gaa ccc tgt aca 624
Asn Val Thr Ser Ala Gly Glu Asp Gly Ile Tyr Tyr Glu Pro Cys Thr
195 200 205
gct aat tgc act ggt tac gct gcc aat gtt ttt gcc act gat tcc aat 672
Ala Asn Cys Thr Gly Tyr Ala Ala Asn Val Phe Ala Thr Asp Ser Asn
210 215 220
ggc cat ata cca gaa ggt ttt agt ttt aat aat tgg ttt ctt tta tcc 720
Gly His Ile Pro Glu Gly Phe Ser Phe Asn Asn Trp Phe Leu Leu Ser
225 230 235 240
aat gac tcc act ttg ttg cat ggt aaa gtt gtt tcc aac caa ccc ttg 768
Asn Asp Ser Thr Leu Leu His Gly Lys Val Val Ser Asn Gln Pro Leu
245 250 255
ttg gtc aat tgt ctt ttg gcc att cct aag att tat gga cta ggc caa 816
Leu Val Asn Cys Leu Leu Ala Ile Pro Lys Ile Tyr Gly Leu Gly Gln
260 265 270
ttt ttc tca ttc aat cac act atg gat ggc gtt tgt aat gga gct gct 864
Phe Phe Ser Phe Asn His Thr Met Asp Gly Val Cys Asn Gly Ala Ala
275 280 285
gtt gat cgt gcc cca gag gct ctg agg ttt aat att aat gac acc tcc 912
Val Asp Arg Ala Pro Glu Ala Leu Arg Phe Asn Ile Asn Asp Thr Ser
290 295 300
gtc att ctt gct gaa ggc tca att gtt ctt cat act gct tta gga aca 960
Val Ile Leu Ala Glu Gly Ser Ile Val Leu His Thr Ala Leu Gly Thr
305 310 315 320
aat ctt tct ttt gtt tgc agt aat tcc tca gat cct cat tta gcc atc 1008
Asn Leu Ser Phe Val Cys Ser Asn Ser Ser Asp Pro His Leu Ala Ile
325 330 335
ttt gcc ata cct ctg ggt gct act gaa gtt ccc tac tat tgc ttt ctt 1056
Phe Ala Ile Pro Leu Gly Ala Thr Glu Val Pro Tyr Tyr Cys Phe Leu
340 345 350
aaa gtt gat act tac aac tcc act gtt tat aaa ttc ttg gct gtt tta 1104
Lys Val Asp Thr Tyr Asn Ser Thr Val Tyr Lys Phe Leu Ala Val Leu
355 360 365
cct cct act gtc agg gaa att gtc atc acc aag tat ggt gat gtt tat 1152
Pro Pro Thr Val Arg Glu Ile Val Ile Thr Lys Tyr Gly Asp Val Tyr
370 375 380
gtc aat ggt ttt ggc tat ttg cat ctc ggt ttg ttg gat gct gtc aca 1200
Val Asn Gly Phe Gly Tyr Leu His Leu Gly Leu Leu Asp Ala Val Thr
385 390 395 400
att aat ttc act ggt cat ggc act gac gat gac gtt tca ggt ttc tgg 1248
Ile Asn Phe Thr Gly His Gly Thr Asp Asp Asp Val Ser Gly Phe Trp
405 410 415
acc ata gca tct act aat ttt gtt gat gca ctc atc gag gtt caa gga 1296
Thr Ile Ala Ser Thr Asn Phe Val Asp Ala Leu Ile Glu Val Gln Gly
420 425 430
act tcc att cag cgt att ctt tat tgt gat gat cct gtt agc caa ctc 1344
Thr Ser Ile Gln Arg Ile Leu Tyr Cys Asp Asp Pro Val Ser Gln Leu
435 440 445
aag tgt tct cag gtt gct ttt gac ctt gac gat ggt ttt tac ccc atc 1392
Lys Cys Ser Gln Val Ala Phe Asp Leu Asp Asp Gly Phe Tyr Pro Ile
450 455 460
tct tct aga aac ctt ctg agt cat gaa cag cca att tct ttt gtt act 1440
Ser Ser Arg Asn Leu Leu Ser His Glu Gln Pro Ile Ser Phe Val Thr
465 470 475 480
ttg cca tca ttt aat ggt ggc ggt ggc tct ggc gga ggt ggg agc ggc 1488
Leu Pro Ser Phe Asn Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
485 490 495
ggt ggt ggc agc aaa gct tta gaa gaa gca aac agc aaa tta gct gct 1536
Gly Gly Gly Ser Lys Ala Leu Glu Glu Ala Asn Ser Lys Leu Ala Ala
500 505 510
ctt gaa aaa ctt aac aaa gag ctt gaa gaa agc aag aaa tta aca gaa 1584
Leu Glu Lys Leu Asn Lys Glu Leu Glu Glu Ser Lys Lys Leu Thr Glu
515 520 525
aaa gaa aaa gct gag cta caa gca aaa ctt gaa gca gaa gca aaa gca 1632
Lys Glu Lys Ala Glu Leu Gln Ala Lys Leu Glu Ala Glu Ala Lys Ala
530 535 540
ctc aaa gaa caa tta gcg aaa caa gct gaa gaa ctt gca aaa cta aga 1680
Leu Lys Glu Gln Leu Ala Lys Gln Ala Glu Glu Leu Ala Lys Leu Arg
545 550 555 560
gct gga aaa gca tca gac tca caa acc cct gat gca aaa cca gga aac 1728
Ala Gly Lys Ala Ser Asp Ser Gln Thr Pro Asp Ala Lys Pro Gly Asn
565 570 575
aaa gtt gtt cca ggt aaa ggt caa gca cca caa gca ggt aca aaa cct 1776
Lys Val Val Pro Gly Lys Gly Gln Ala Pro Gln Ala Gly Thr Lys Pro
580 585 590
aac caa aac aaa gca cca atg aag gaa act aag aga cag tta cca tca 1824
Asn Gln Asn Lys Ala Pro Met Lys Glu Thr Lys Arg Gln Leu Pro Ser
595 600 605
aca ggt gaa aca gct aac cca ttc ttc aca gcg gca gcc ctt act gtt 1872
Thr Gly Glu Thr Ala Asn Pro Phe Phe Thr Ala Ala Ala Leu Thr Val
610 615 620
atg gca aca gct gga gta gca gca gtt gta aaa cgc aaa gaa gaa aac 1920
Met Ala Thr Ala Gly Val Ala Ala Val Val Lys Arg Lys Glu Glu Asn
625 630 635 640
<210> 2
<211> 640
<212> PRT
<213> Artifical sequence
<400> 2
Met Asp Val Thr Arg Cys Gln Ser Thr Thr Asn Phe Arg Arg Phe Phe
1 5 10 15
Ser Lys Phe Asn Val Gln Ala Pro Ala Val Val Val Leu Gly Gly Tyr
20 25 30
Leu Pro Ser Met Asn Ser Ser Ser Trp Tyr Cys Gly Thr Gly Ile Glu
35 40 45
Thr Ala Ser Gly Val His Gly Ile Phe Leu Ser Tyr Ile Asp Ser Gly
50 55 60
Gln Gly Phe Glu Ile Gly Ile Ser Gln Glu Pro Phe Asp Pro Ser Gly
65 70 75 80
Tyr Gln Leu Tyr Leu His Lys Ala Thr Asn Gly Asn Thr Asn Ala Ile
85 90 95
Ala Arg Leu Arg Ile Cys Gln Phe Pro Asp Asn Lys Thr Leu Gly Pro
100 105 110
Thr Val Asn Asp Val Thr Thr Gly Arg Asn Cys Leu Phe Asn Lys Ala
115 120 125
Ile Pro Ala Tyr Met Arg Asp Gly Lys Asp Ile Val Val Gly Ile Thr
130 135 140
Trp Asp Asn Asp Arg Val Thr Val Phe Ala Asp Lys Ile Tyr His Phe
145 150 155 160
Tyr Leu Lys Asn Asp Trp Ser Arg Val Ala Thr Arg Cys Tyr Asn Arg
165 170 175
Arg Ser Cys Ala Met Gln Tyr Val Tyr Thr Pro Thr Tyr Tyr Met Leu
180 185 190
Asn Val Thr Ser Ala Gly Glu Asp Gly Ile Tyr Tyr Glu Pro Cys Thr
195 200 205
Ala Asn Cys Thr Gly Tyr Ala Ala Asn Val Phe Ala Thr Asp Ser Asn
210 215 220
Gly His Ile Pro Glu Gly Phe Ser Phe Asn Asn Trp Phe Leu Leu Ser
225 230 235 240
Asn Asp Ser Thr Leu Leu His Gly Lys Val Val Ser Asn Gln Pro Leu
245 250 255
Leu Val Asn Cys Leu Leu Ala Ile Pro Lys Ile Tyr Gly Leu Gly Gln
260 265 270
Phe Phe Ser Phe Asn His Thr Met Asp Gly Val Cys Asn Gly Ala Ala
275 280 285
Val Asp Arg Ala Pro Glu Ala Leu Arg Phe Asn Ile Asn Asp Thr Ser
290 295 300
Val Ile Leu Ala Glu Gly Ser Ile Val Leu His Thr Ala Leu Gly Thr
305 310 315 320
Asn Leu Ser Phe Val Cys Ser Asn Ser Ser Asp Pro His Leu Ala Ile
325 330 335
Phe Ala Ile Pro Leu Gly Ala Thr Glu Val Pro Tyr Tyr Cys Phe Leu
340 345 350
Lys Val Asp Thr Tyr Asn Ser Thr Val Tyr Lys Phe Leu Ala Val Leu
355 360 365
Pro Pro Thr Val Arg Glu Ile Val Ile Thr Lys Tyr Gly Asp Val Tyr
370 375 380
Val Asn Gly Phe Gly Tyr Leu His Leu Gly Leu Leu Asp Ala Val Thr
385 390 395 400
Ile Asn Phe Thr Gly His Gly Thr Asp Asp Asp Val Ser Gly Phe Trp
405 410 415
Thr Ile Ala Ser Thr Asn Phe Val Asp Ala Leu Ile Glu Val Gln Gly
420 425 430
Thr Ser Ile Gln Arg Ile Leu Tyr Cys Asp Asp Pro Val Ser Gln Leu
435 440 445
Lys Cys Ser Gln Val Ala Phe Asp Leu Asp Asp Gly Phe Tyr Pro Ile
450 455 460
Ser Ser Arg Asn Leu Leu Ser His Glu Gln Pro Ile Ser Phe Val Thr
465 470 475 480
Leu Pro Ser Phe Asn Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
485 490 495
Gly Gly Gly Ser Lys Ala Leu Glu Glu Ala Asn Ser Lys Leu Ala Ala
500 505 510
Leu Glu Lys Leu Asn Lys Glu Leu Glu Glu Ser Lys Lys Leu Thr Glu
515 520 525
Lys Glu Lys Ala Glu Leu Gln Ala Lys Leu Glu Ala Glu Ala Lys Ala
530 535 540
Leu Lys Glu Gln Leu Ala Lys Gln Ala Glu Glu Leu Ala Lys Leu Arg
545 550 555 560
Ala Gly Lys Ala Ser Asp Ser Gln Thr Pro Asp Ala Lys Pro Gly Asn
565 570 575
Lys Val Val Pro Gly Lys Gly Gln Ala Pro Gln Ala Gly Thr Lys Pro
580 585 590
Asn Gln Asn Lys Ala Pro Met Lys Glu Thr Lys Arg Gln Leu Pro Ser
595 600 605
Thr Gly Glu Thr Ala Asn Pro Phe Phe Thr Ala Ala Ala Leu Thr Val
610 615 620
Met Ala Thr Ala Gly Val Ala Ala Val Val Lys Arg Lys Glu Glu Asn
625 630 635 640

Claims (10)

1. porcine epizootic diarrhea S 1The proteantigen fusion gene is characterized in that: its polynucleotide sequence is shown in the SEQ ID No.1.
2. by the said fusion gene encoded protein of claim 1, it is characterized in that: its aminoacid sequence is shown in the SEQ ID No.2.
3. the recombinant expression vector that contains the said fusion gene of claim 1.
4. contain the recombinant host strain of the said recombinant expression vector of claim 3.
5. according to the described recombinant host strain of claim 4, it is characterized in that: described recombinant host strain be the reorganization bacillus megaterium ( Bacillus megaterium) bacterial strain, its microbial preservation number is: CCTCC No:M2011445.
6. the described porcine epizootic diarrhea S1 of claim 1 proteantigen fusion gene is prevented and treated the purposes in the porcine epizootic diarrhea vaccine in preparation.
7. the described albumen of claim 2 is prevented and treated the purposes in the porcine epizootic diarrhea vaccine in preparation.
8. the described expression vector of claim 3 is prevented and treated the purposes in the porcine epizootic diarrhea vaccine in preparation.
9. claim 4 or 5 described recombinant host strains prevent and treat the purposes in the porcine epizootic diarrhea vaccine in preparation.
10. according to the described purposes of claim 6-9, it is characterized in that: described vaccine is the mucosal immunity live bacterial vaccines.
CN2011104247048A 2011-12-16 2011-12-16 Porcine epidemic diarrhea S1 protein fusion gene, recombinant bacillus megaterium strain and application Pending CN102399806A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2011104247048A CN102399806A (en) 2011-12-16 2011-12-16 Porcine epidemic diarrhea S1 protein fusion gene, recombinant bacillus megaterium strain and application
CN201210523652.4A CN103194472B (en) 2011-12-16 2012-12-06 Porcine epizootic diarrhea virus S1 protein fusion gene and recombinant bacillus megaterium, and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011104247048A CN102399806A (en) 2011-12-16 2011-12-16 Porcine epidemic diarrhea S1 protein fusion gene, recombinant bacillus megaterium strain and application

Publications (1)

Publication Number Publication Date
CN102399806A true CN102399806A (en) 2012-04-04

Family

ID=45882453

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011104247048A Pending CN102399806A (en) 2011-12-16 2011-12-16 Porcine epidemic diarrhea S1 protein fusion gene, recombinant bacillus megaterium strain and application
CN201210523652.4A Active CN103194472B (en) 2011-12-16 2012-12-06 Porcine epizootic diarrhea virus S1 protein fusion gene and recombinant bacillus megaterium, and their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210523652.4A Active CN103194472B (en) 2011-12-16 2012-12-06 Porcine epizootic diarrhea virus S1 protein fusion gene and recombinant bacillus megaterium, and their use

Country Status (1)

Country Link
CN (2) CN102399806A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103585625A (en) * 2013-11-29 2014-02-19 华南农业大学 Porcine epidemic diarrhea recombinant baculovirus gene engineering subunit vaccine, preparation method and application thereof
CN104046637A (en) * 2014-07-03 2014-09-17 南京农业大学 Recombinant S1 protein of novel mutant strain of porcine epidemic diarrhea virus and subunit vaccine of recombinant S1 protein
CN104513827A (en) * 2013-09-30 2015-04-15 普莱柯生物工程股份有限公司 Porcine epizootic diarrhea virus strain, attenuated vaccine strain thereof and application thereof
WO2015138455A1 (en) * 2014-03-11 2015-09-17 Regents Of The University Of Minnesota Porcine epidemic diarrhea virus vaccines and methods of use thereof
CN106188249A (en) * 2016-07-13 2016-12-07 北京农学院 For detecting the antigen of PEDV variant antibody and method and test kit
US9950061B2 (en) 2014-04-03 2018-04-24 Boehringer Ingelheim Vetmedica, Inc. Porcine epidemic diarrhea virus vaccine

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104946686A (en) * 2015-05-29 2015-09-30 广东大华农动物保健品股份有限公司 Recombinant plasmid for expressing M protein, N protein and S1 protein in porcine epidemic diarrhea proteins, and construction method and application thereof
CN106554944B (en) * 2015-09-28 2020-04-14 普莱柯生物工程股份有限公司 Porcine epidemic diarrhea virus low-virulent strain, vaccine composition prepared from porcine epidemic diarrhea virus low-virulent strain and application of vaccine composition
CN106188307B (en) * 2016-07-06 2019-01-04 长沙爱科博生物科技有限公司 A kind of fusion protein, preparation method and a boar oral vaccine or drug
CN108611325A (en) * 2018-04-25 2018-10-02 南方医科大学 A kind of preparation method of porcine epidemic diarrhea resisting virus S1 protein hybridoma cell strains
CN113318223B (en) * 2021-04-22 2021-12-31 湖南兀邦生物科技有限公司 Classical swine fever virus and porcine epidemic diarrhea virus subunit combined vaccine and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101892189B (en) * 2010-07-05 2012-07-04 浙江大学 Transformant for blocking effect of porcine somatostatin by oral immunization and application thereof

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104513827A (en) * 2013-09-30 2015-04-15 普莱柯生物工程股份有限公司 Porcine epizootic diarrhea virus strain, attenuated vaccine strain thereof and application thereof
CN104513827B (en) * 2013-09-30 2018-02-13 普莱柯生物工程股份有限公司 A kind of Porcine epidemic diarrhea virus strain, its attenuated vaccine strain and application
CN103585625A (en) * 2013-11-29 2014-02-19 华南农业大学 Porcine epidemic diarrhea recombinant baculovirus gene engineering subunit vaccine, preparation method and application thereof
CN103585625B (en) * 2013-11-29 2015-12-02 华南农业大学 A kind of porcine epizootic diarrhea recombinant baculovirus genetic engineering subunit vaccine and preparation method thereof and application
WO2015138455A1 (en) * 2014-03-11 2015-09-17 Regents Of The University Of Minnesota Porcine epidemic diarrhea virus vaccines and methods of use thereof
CN106535930A (en) * 2014-03-11 2017-03-22 明尼苏达大学董事会 Porcine epidemic diarrhea virus vaccines and methods of use thereof
US10034934B2 (en) 2014-03-11 2018-07-31 Regents Of The University Of Minnesota Porcine epidemic diarrhea virus vaccines and methods of use thereof
US9950061B2 (en) 2014-04-03 2018-04-24 Boehringer Ingelheim Vetmedica, Inc. Porcine epidemic diarrhea virus vaccine
US10702601B2 (en) 2014-04-03 2020-07-07 Boehringer Ingelheim Animal Health USA Inc. Porcine epidemic diarrhea virus vaccine
CN104046637A (en) * 2014-07-03 2014-09-17 南京农业大学 Recombinant S1 protein of novel mutant strain of porcine epidemic diarrhea virus and subunit vaccine of recombinant S1 protein
CN106188249A (en) * 2016-07-13 2016-12-07 北京农学院 For detecting the antigen of PEDV variant antibody and method and test kit

Also Published As

Publication number Publication date
CN103194472A (en) 2013-07-10
CN103194472B (en) 2015-06-03

Similar Documents

Publication Publication Date Title
CN103194472B (en) Porcine epizootic diarrhea virus S1 protein fusion gene and recombinant bacillus megaterium, and their use
CN104248762B (en) A kind of pig epidemic diarrhea vaccine combination and its preparation method and application
Zhou et al. A novel multivalent vaccine based on secretary antigen-delivery induces protective immunity against Vibrio anguillarum and Aeromonas hydrophila
CN109867727B (en) Flagellin-fiber2 fusion protein, and preparation method and application thereof
Huang et al. Construction and immunogenicity analysis of Lactobacillus plantarum expressing a porcine epidemic diarrhea virus S gene fused to a DC-targeting peptide
CN107529534B (en) Protective antigen of avibacterium paragallinarum, expression and application thereof
CN116019906A (en) Novel coronavirus immunogenic composition, preparation method and application thereof
CN101687024A (en) trypanosoma antigens, vaccine compositions, and related methods
CN110408637A (en) A kind of hemorrhagic disease of grass carp yeast oral vaccine and application
CN107099496A (en) Recombinant strains of lactic acid bacteria of amalgamation and expression infections chicken cloacal bursa virus VP2 albumen and Salmonella outer membrane protein and application thereof
CN107227311A (en) Recombination porcine parvovirus like-particles and its preparation method and application
CN109303916A (en) Coke dies GAP-associated protein GAP GSDMD and is preparing the application in ghost vaccine
Sha et al. Recombinant Lactococcus Lactis expressing M1-HA2 fusion protein provides protective mucosal immunity against H9N2 avian influenza virus in chickens
CN101838658B (en) O type foot-and-mouth disease virus variant as well as coding gene and application thereof
CN105907766B (en) The recombinant yeast pichia pastoris and its construction method of expression goat alpha interferon and application
CN104894045B (en) A kind of recombinant Lactobacillus and its preparation method and application of coexpression VP 1 Gene of Foot-and-Mouth Disease virus and immunologic adjuvant ox IL-6 genes
CN103614387B (en) The carrying Cap gene of porcine circovirus type 2 gene optimized and recombinant plasmid and application
CN103194471B (en) Transmissible gastroenteritis of swine S/N protein fusion gene and Recombinant Lactococcus lactis and application
CN103275228A (en) K99-987P-F41 recombinant protein and application thereof
CN100567477C (en) Express the recombination lactic acid galactococcus and the method for making of pig infectious gastroenteritis virus S protein
CN107446872A (en) A kind of recombinant lactic acid bacteria vaccine strain of constitutive expression rabbit hemorrhagic disease virus VP60 albumen and its production and use
CN103409455A (en) Egg yolk antibody anti-human enterotoxigenic escherichia coli adhesion protein and application thereof
CN104479028B (en) Bovine rota VP8* subunits recombinate chimeric protein and its application
CN103194470B (en) Swine transmissible gastroenteritis virus antigen fusion gene and recombinant bacillus megaterium, and their use
Shonyela et al. Recombinant Lactobacillus plantarum NC8 strain expressing porcine rotavirus VP7 induces specific antibodies in BALB/c mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120404